2023年7月12日

蒙特利爾,2021年6月17日——溝實驗室,蒙特利爾精密醫學公司正在開發一種新的戒煙係統就完成了一輪130萬美元的融資。從左到右:奧利弗波旁(聯合創始人及首席技術官),Laurent Laferriere(聯合創始人兼首席執行官),克盧斯,博士(合作夥伴和研究主任)蒙特利爾啟動關閉計劃輪與放大資本的參與2021年5月,德斯賈丁斯首都北方企業,和魁北克Formentera首都醫療創新的交響樂保健網絡,以及著名的科技企業家如Cherif哈比卜(對話)的首席執行官和西蒙·德·比恩(GSoft首席執行官),等等。解決一個巨大的未滿足的需要吸煙仍然是這一天可預防死亡的首要原因直接與1每5人死亡與吸煙有關。即使超過三分之二的吸煙者想戒煙根據疾病控製和預防中心,平均戒煙的成功率一直徘徊在7%沒有任何改善的跡象。“問題的一部分是,當前的戒煙產品尋求治療一個非常複雜的癮,放之四海而皆準的方法。溝是第一個解決方案適應其在實時處理,基於渴望強度和行為的反饋。”- Laurent Laferriere聯合創始人兼首席執行官,溝實驗室溝裏的解決方案由Laurent Laferriere Olivier波旁,兩個連續創業者,溝實驗室提供了一個革命性的戒煙的解決方案通過開發DitchPen™,新醫療汽化器精確劑量尼古丁的數量,以減少它自動逐步和個性化。醫療設備是搭配了一個移動應用程序,使用機器學習算法學習,適應和作為行為助理在整個撤離過程。的DitchPen™和移動應用程序。“的DitchPen™之間的集合點是人工智能技術和尼古丁替代療法。 Nicotine addiction is an intricate disease linked to psychological, social and biological factors. Each cessation journey is unique and the tools to achieve abstinence must take every factor into account. The use of the Ditch system represents a new paradigm of cessation support based on a dynamic, progressive and personalized program.” — Olivier Bourbonnais, co-founder & CTO, Ditch Labs The capital injection will allow the company to pursue preclinical studies, advance its global regulatory plan and further product and algorithm development. The company plans to market a first version of the DitchPen™ in the UK in 2022 and in Canada in 2024, following a rigorous regulatory process to approve the DitchPen™ as an aid to smoking cessation. “Amplify Capital is excited to partner with Laurent Laferrière, Olivier Bourbonnais and the stellar team at Ditch on its mission to reduce nicotine addiction at scale by providing a device, data, behavioral support and insights to drastically improve smoking cessation rates beyond current methods which haven’t changed in decades. The impact of quitting smoking has benefits to the individual, their families, their workplace, their communities and society that can reduce costs and improve health as a whole.” — Kathryn Wortsman, Managing Partner, Amplify Capital